Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

26.10.21	MÄRKTE USA/Wall Street zum Start mit Aufschlägen erwartet (Dow Jones)
26.10.21	Lilly Lifts FY21 Adj. EPS, Revenue View Above Market - Quick Facts (RTTNews)
26.10.21	Eli Lilly And Co. Profit Drops In Q3 (RTTNews)
26.10.21	Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential (PR Newswire)
26.10.21	Ausblick: Eli Lilly and zieht Bilanz zum abgelaufenen Quartal (finanzen.net) So sehen die Prognosen der Experten für die Eli Lilly and-Bilanz aus.» mehr
19.10.21	Lilly : Phase 3 Tirzepatide Results Show Superior A1C And Body Weight Reductions In Type 2 Diabetes (RTTNews)
19.10.21	Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk (PR Newswire)
18.10.21	Lilly Declares Fourth-Quarter 2021 Dividend (PR Newswire)
14.10.21	Lilly Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Presented at ESMO Virtual Plenary and Simultaneously Published in the Annals of Oncology (PR Newswire)
13.10.21	Eli Lilly: FDA Approves Verzenio In Adjuvant Treatment Of HR+ HER2- Early Breast Cancer (RTTNews)
13.10.21	FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer (PR Newswire)
12.10.21	Lilly Confirms Date and Conference Call for Third-Quarter 2021 Financial Results Announcement (PR Newswire)
12.10.21	COVAX Exercises Option To Purchase 176.5 Mln Addl Doses Of Moderna COVID-19 Vaccine In H1 2022 (RTTNews)
11.10.21	Erste Schätzungen: Eli Lilly and präsentiert Quartalsergebnisse (finanzen.net) Eli Lilly and legt die jüngste Bilanz offen. Was Analysten erwarten.» mehr
07.10.21	Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
07.10.21	Sonoco To Implement Price Increase For Uncoated Recycled Paperboard (RTTNews)
04.10.21	Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals (PR Newswire)
01.10.21	At Week 104, 75% of Patients with Ulcerative Colitis Taking Mirikizumab Maintained Symptomatic Remission in Phase 2 Study (PR Newswire)
30.09.21	Lilly, Incyte Present Detailed Results From OLUMIANT BRAVE-AA1, BRAVE-AA2 Trials In Alopecia Areata (RTTNews)
30.09.21	OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata (PR Newswire)
30.09.21	Lilly Reports Positive Results From Two SURPASS-3 Sub-studies Of Tirzepatide In Type 2 Diabetes (RTTNews)
30.09.21	Lilly's tirzepatide led to greater improvements in liver fat content compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 MRI sub-study (PR Newswire)
30.09.21	Lilly's tirzepatide led to greater time in range compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 CGM sub-study (PR Newswire)
29.09.21	Lilly and Susan G. Komen® Partner to Address Disparities in Breast Cancer Outcomes Experienced By Black Women (PR Newswire)
29.09.21	FDA Expands Lilly's Erbitux Label With Braftovi For Treatment Of Metastatic Colorectal Cancer (RTTNews)
28.09.21	FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy (PR Newswire)
28.09.21	Lilly Cuts List Price Of Insulin Lispro Injection In U.S. Again, Effective Jan. 1 (RTTNews)
28.09.21	Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options (PR Newswire)
27.09.21	New Data from Verzenio® (abemaciclib) monarchE Study to Be Featured in ESMO Virtual Plenary (PR Newswire)
27.09.21	Lilly Recalls One Lot Of GLUCAGON Emergency Kit (RTTNews)
25.09.21	Eli Lilly and Company Issues Voluntary Nationwide Recall of One Lot of GLUCAGON® Emergency Kit Due to Loss of Potency (PR Newswire)
21.09.21	EU-Kommission sichert sich Eli Lillys COVID-19-Medikament - Aktie schwächer (AWP) Die EU-Kommission hat einen Rahmenvertrag über die gemeinsame Anschaffung eines COVID-19-Medikaments des Pharmaunternehmens Eli Lilly abgeschlossen.» mehr
21.09.21	Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities (PR Newswire)
21.09.21	Lilly announces procurement agreement with European Commission to supply bamlanivimab and etesevimab together for the treatment of confirmed COVID-19 (PR Newswire)
21.09.21	Lilly Announces the Early Tender Results of Its Pending Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities and Removal of the Note Caps... (PR Newswire)
17.09.21	MÄRKTE USA/Wall Street im Bann von China und "Hexensabbat" (Dow Jones)
17.09.21	MÄRKTE USA/Wall Street am Verfalltag mit leichten Abgaben (Dow Jones)
17.09.21	MÄRKTE USA/Wall Street am Verfalltag vor leichten Verlusten (Dow Jones)
16.09.21	FDA Expands EUA For Lilly's Bamlanivimab, Etesevimab To Include Post-exposure Prophylaxis For COVID (RTTNews)
16.09.21	Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19 (PR Newswire)
15.09.21	Lilly To Supply 388,000 Doses Of Etesevimab To U.S. For Treatment Of COVID-19 (RTTNews)
15.09.21	Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19 (PR Newswire)
13.09.21	Lilly to Participate in the 2021 Cantor Virtual Global Healthcare Conference (PR Newswire)
13.09.21	Lilly to Present New Data from Oncology Portfolio at ESMO Congress (PR Newswire)
09.09.21	Lilly Prices First Sustainability Bond to Advance Global ESG Strategy (PR Newswire)
09.09.21	Eli Lilly Reports Breakthrough Therapy Designation For Jardiance - Quick Facts (RTTNews)
09.09.21	FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction (PR Newswire)
08.09.21	Eli Lilly and Company -- Moody's rates Eli Lilly's notes A2; stable outlook (Moodys)
07.09.21	Lilly Diabetes joins The Leona M. and Harry B. Helmsley Charitable Trust to pledge significant funding to "Type 1 Diabetes Camps Initiative" (PR Newswire)
07.09.21	Eli Lilly Begins Cash Tender Offer Of Specified Series Of Outstanding Debt Securities (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

16:21		Bayer-Aktie in Grün: Weiterer Studienerfolg
16:19		Pharmakonzern STADA vor milliardenschwerem Börsengang
16:13		Novartis-Aktie höher: Novartis kooperiert mit Light Horse Therapeutics
15:59		STOXX 50 aktuell: So performt der STOXX 50 am Nachmittag
15:59		Starker Wochentag in Zürich: SMI nachmittags im Plus
15:59		Angespannte Stimmung in Frankfurt: LUS-DAX fällt nachmittags
15:59		Handel in Europa: Euro STOXX 50 fester
15:58		Aktienempfehlung Novartis-Aktie: Goldman Sachs Group Inc. bewertet Anteilsschein in neuer Analyse

16:21

Bayer-Aktie in Grün: Weiterer Studienerfolg

16:19

Pharmakonzern STADA vor milliardenschwerem Börsengang

16:13

Novartis-Aktie höher: Novartis kooperiert mit Light Horse Therapeutics

15:59

STOXX 50 aktuell: So performt der STOXX 50 am Nachmittag

15:59

Starker Wochentag in Zürich: SMI nachmittags im Plus

15:59

Angespannte Stimmung in Frankfurt: LUS-DAX fällt nachmittags

15:59

Handel in Europa: Euro STOXX 50 fester

15:58

Aktienempfehlung Novartis-Aktie: Goldman Sachs Group Inc. bewertet Anteilsschein in neuer Analyse

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	30.39	2.95 %	K V
Part Grp Hldg	1’332.00	2.54 %	K V
Roche Hldg G	272.20	1.99 %	K V
Givaudan	3’938.00	1.44 %	K V
Novartis	91.70	0.81 %	K V
Geberit	503.40	-0.47 %	K V
CieFinRichemont	139.95	-0.71 %	K V
Zurich Insur Gr	541.80	-0.99 %	K V
Swiss Re	133.40	-1.04 %	K V
Kuehne+Nagel Int	203.20	-2.03 %	K V

Nachrichten zu Eli Lilly

Aktien Top/Flop

Eli Lilly Peer Group Nachrichten

Meistgelesene Nachrichten